Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Haroche, Julien; Cohen‐Aubart, Fleur; Emile, Jean‐François; Arnaud, Laurent; Maksud, Philippe; Charlotte, Frédéric; Cluzel, Philippe; Drier, A.; Hervier, B.; Benameur, Neïla; Besnard, Sophie; Donadieu, Jean; Amoura, Zahir

doi:10.1182/blood-2012-07-446286

Public

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Published in Blood • Dec 22, 2012

Authors:

Julien Haroche

Fleur Cohen‐Aubart

Jean‐François Emile

Abstract

Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis. BRAFV600E gain-of-function mutations have been observed in 57% of cases of Langerhans cell histiocytosis (LCH) and 54% of cases of Erdheim-Chester disease (ECD), but not in other types of histiocytoses. Targeted ...

Subject

Erdheim–Chester disease

Vemurafenib

Langerhans cell histiocytosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!